Background: We describe a case of a recurrent ocular surface squamous neoplasia (OSSN) in a37 -year-old male with a mass at the infero-temporal quadrant along with an isolated primary lesion at the upper nasal quadrant for the last five months with a past history of surgical excision 7 years ago for a nodular mass in the same eye. The mass showed delayed response to Mitomycin C (MMC) therapy and finally developed limbal stem cell deficiency.
Introduction
Ocular surface squamous neoplasia (OSSN) is a disease of the elderlyl, having predilection forthe interpalpebral are4 mostly the corneoscleral limbust in 87.8 Vo of cases. Management can be either surgical orbytopical mitomycin C (MMC) drops. We report a case of OSSN in which the inferior and superior limbus were involved in a young adult, showed delayed recurrence after surgery took an unusually prolonged time for complete resolution wittr topical MMC andfinally resultedin limbal stem cell deficiency (LSCD).
Case report
A 37-year old male shopkeeper presented with nvo gndually increasing, masses in the left eye over five months. The past history revealed temporal limbal mass excision in the same eye seven years ago for anodule atthe temporal limbus. On examination, best corrected visual acuity (BCVA) was 20130 left eye (LE) and2Dl2Dighteye (RE).
.na?"* :,i.o,';l;, i..f a examination of thel .F.revealedtwo separate, raised masses, pale pink in colour with a scaly surface at the inferior (5.5mm x 4mm) and superior (5mm x 3.5mm) limbus, invading 2mm into the cor-nea (Fig.1a) . The anterior chamber (AC) was clear. Intraocularpressure was 16 mm in both eyes. There was no lymphadenopathy or any systemic abnormalities.
A provisional diagnosis of recurrent OSSN was made, and confirmed by impression cytology (IC). Intraocular invasion was ruled out by ultrasound biomicroscopy (UBM) (Frg.1b). The ELISA test forHuman Immunodeficiency Virus (IilV), done after taking patient's informed consent, was negative.
Topical MMC (0.02 Vo), four times a day, in a cyclic manner, one week on the drug and one week off it was started. As there was no improvement after three cycles, Interferon alpha=2 b (INF 6-2b) drops (1 million IU/ml) was suggested but refused by the patient due to its cost. Topical MMC concentration was increased to 0.04 To.After two subsequent cycles, a remarkable chemoreduction was noticed and complete resolution qccuned after two more cycles, following which the drug was discontinued. The patient did not show any signs or symptoms of drug intolerance during the therapy except for a mild irritation off and on which, however, subsided with topical non-steroidal antiinflammatory drops twice daily and a tear substitute four times a day. fre-and post-treatment specular microscopic findings were within normal limits. The BCVAwas stable. The IC at six months revealed no abnormality.
At the ten-month follow-up, the cornea was lustureless with multiple superficial vascularisation indicating limbal stem cell deficiency (Ftg. 2a) and with a BCVA of 20140.IC revealed the presence of a few conjunctival goblet cells @g 2b). Instillation of frequenttopical lubricant drops, two hourly, was advised. There was no recuffence after two vears of follow-up. Recunence usually occurs within the first two years of resolution but in the present case, it was delayed for seven years, which could be due to the presence of subclinical tumor cells. (v) The unusual but significantfinding was the developmentof LSCD. LSCD followingMMC is less expectedthan after wide surgical excision where there is the possibility of direct damage of the limbal stem cells (Khong et al 2006) . If it does occur, it may be attributed to the diffuse tumorlocation ratherthan to the MMC per se (Khong et a12006) , The delayed response in the case under report could be multifactorial: (i) the use ofless concentrated drops, or (ii) less potent drops and (iii) a poor compliance of the patient. The first factor was ruled out as the use of less concentrated drops 0.02 7o is universally accepted for OSSN (Panda et al 2008 ; Sepulveda et al 20 10) . The second maynotbe apossibility as the drug is routinely prepared in our own pharmacy adopting Panda A et al Recurrent OSSN Nepal J Ophthalmol 20II; the same formulation. Regarding the third, though a firm opinion cannot be given, the patient appears to becompliant.
In summary, the concept that OSSN is a disease of the elderly and in immunocompromisedpersons does not hold good for the present case. Young and healthy individuals may be affected by OSSN even without being associated with HIV Recunence following incomplete removal of the neoplasia does occur, but recurrence after seven years is apparently rare for which constant follow-up for these patients is a must. Complete resolution after topical MMC, which usually takes fourcycles, maybe delayedin some situations (Lee et al I99 5 ; Fucht et al 1997 ; Chen et al z004) .Whetherthis delay in the present caseis as aresultof its atypical andrecurrentnature or due to an inadequate drug concentration cannot be commented on the basis of a single case report. Long-term use of the prescribed drug, more than four to five cycles, is further a matter of concem as far as complications are concerned.
Thus, we would like to reiterate that if there is a delayed response to MMC, efforts should be made to find out the exact cause and the patient should be monitored constantly both during therapy and following complete resolution (Lee et al 1995) . Though more aggressive surveillance is recommended in the first two years of follow-up, long-termfollow-up is essential as recuffences can occureven manyyears later, as evidentin theprcsent case.
